Ranjan Pai is the chairman of Manipal Group. He is a prominent figure known for his investment in startups like Byju’s and PharmEasy. His recent investments in ventures like Aakash Institute, Bluestone, and FirstCry highlight his dedication to cultivating innovation and driving growth in the Indian startup ecosystem.
He has a family and career background deeply rooted in the education and healthcare sectors. This is reflected in his ventures, including his role as the managing director of Melaka Manipal Medical College in Malaysia and as the founder of MEMG. Today, MEMG is a global healthcare and education conglomerate worth $3 billion.
Ranjan Pai has also received various accolades for his contributions to the healthcare and education industries. He has been awarded as Ernst & Young Entrepreneur of the Year Award, Padma Shri Award, and the NDTV Indian of the Year Award.
Joining PharmEasy Board as the Largest Shareholder
Ranjan Pai joined the board of PharmEasy alongside CEO Siddharth Shah, on the board of PharmEasy, where he will have three seats on the board after his investment. His investment of Rs. 3500 crores makes him the largest stakeholder in the company with a 15% stake. This board representation indicates his deepening involvement in the company’s strategic decision-making and future direction.
What is the significance of Ranjan Pai’s investment in PharmEasy?
PharmEasy took on a debt of $300 million from Goldman Sachs, which it aims to repay using the funds raised through the right issue. Pai’s investment will help the company address its debt burden and strengthen its financial position. Ranjan Pai’s investment in PharmEasy is part of his broader ambition to influence the healthcare industry in India. Ranjan Pai’s investment has boosted PharmEasy’s valuation to an estimated $500 to $600 million.
Pharmeasy Growth Trajectory and Industry Impact
PharmEasy’s impact on the healthcare and e-commerce sectors in India is massive. Since the COVID-19 pandemic, it witnessed exponential growth. The Indian masses’ adoption of new-age technologies and the internet drives this growth. The e-pharmacy market in India is projected to grow significantly, reflecting the increasing demand for online healthcare solutions.
Thus, PharmEasy is committed to simplifying the healthcare experience by providing affordable and online deliveries of medicines. This move has cemented PharmEasy’s position as a key player in the online pharmacy and healthcare industry.
Notably, PharmEasy has achieved profitability in the first half of 2023-2024. The company has reported a cumulative EBITDA of Rs. 60 crores for April-September 2023. The current market share of PharmEasy in the online pharmacy sector in India is approximately 15%.
Despite facing tough competition from Tata-owned 1mg, Flipkart’s Health Plus, and Reliance’s Netmeds, Pharmeasy is well-equipped to leverage Pai’s expertise. This will help the company regain market share.
Investing in PharmEasy Shares
Investing in PharmEasy unlisted shares presents certain risks such as liquidity risk and price volatility. Despite these risks, the unlisted shares of PharmEasy have attracted investors. These investors are looking to capitalize on the company’s potential growth and market positioning.
However, you must consider the past and current performance equally while investing in PharmEasy.
The best move is to talk with experts and get their opinions. Stockify is a reliable platform for buying unlisted shares and has a wide range of blue-chip stocks for retail investors. Here, you can easily check the current price of unlisted shares and analyze their performance over the past few years.
Connect with our team to know the best-performing unlisted shares now!
